Foundational course
PLANT MEDICINE ESSENTIALS
Understand LSD, MDMA, 5-MAPB, metocin, psilocybin, DMT and bufo. Explore how they affect the brain, what different intensity labels mean and what research does and does not establish about social microdosing.
Use a private notebook for exercises. Self-check answers open below each lesson. Progress is not yet saved to your account.
Updated September 22, 2026. This library includes synthetic compounds and fungi as well as plant-associated traditions; the course title is not a claim that every substance is botanical.
Course outcomes
WHAT YOU WILL PRACTICE
Language
Separate cultural terms, biological categories and marketing claims.
Evidence
Distinguish an interesting story from a reliable conclusion.
Agency
Build a question list that supports informed personal decisions.
Course curriculum
UNDERSTAND THE DIFFERENCES
LESSON 01Dose, Intensity and the Brain
What dosing means
A dose is an amount of an active substance administered on an occasion. A dosing regimen also includes timing and frequency. Neither tells the whole story without substance identity, formulation, concentration, route and the individual. “One capsule,” “one piece” and “one drop” are product descriptions, not standardized amounts of active drug.
Units matter: a milligram (mg) is one thousand micrograms (µg). A gram of mushroom material is not a gram of psilocybin. The same mass of different substances is not an equivalent exposure. Do not convert a published clinical dose into a product amount or apply one substance’s chart to another.
Microdose
A small exposure intended to avoid a full psychedelic experience, often described as below obvious perceptual effects. There is no universally agreed definition, and some study participants notice effects. The word is not a safety certification.
Low dose
A lower but perceptible exposure. Changes may be subtle yet still affect emotion, attention or judgment. “I can feel it” and “I am functioning normally” are different claims. Low dose and microdose should not be used as synonyms.
Macro / full dose
An informal description of a clearly psychedelic or strongly psychoactive experience, not a universal medical category. It is not automatically therapeutic. For MDMA and 5-MAPB, “full active dose” is more useful than importing a classic-psychedelic label.
Why this guide does not give a take-this-amount chart: these categories vary across substances, studies and routes, and several drugs here lack adequate controlled human data. The profiles explain effects and evidence rather than provide personal dosing, redosing or mixing instructions. A higher amount can change the kind of experience, not just its strength.
Two mechanisms that should not be confused
Receptor activation: a receptor is a cell’s signal-receiving protein. An agonist activates it. Classic psychedelics such as LSD, psilocin and DMT act at serotonin receptors, with 5-HT2A particularly important to psychedelic effects. This changes signaling, rather than simply filling the brain with more serotonin.
Transporter-mediated release: transporters help move and recycle chemical messengers. MDMA, and 5-MAPB in laboratory research, act at these systems to increase monoamine signaling. Norepinephrine is involved in arousal and bodily stress responses; dopamine contributes to motivation and reward processing. These are simplified functions, not one-chemical explanations of an emotion.
Mechanism sources: Tryptamine receptor experiments · NIDA: MDMA pharmacology · Benzofuran transporter experiments.
What “social microdosing” can and cannot mean
Here it describes an intention to use a small amount in a social context. It is not an established medical treatment or proof that any drug improves social skills. Feeling open, wanting company, accurately reading emotions and making good decisions are separate outcomes. Evidence for one does not establish the others.
Likewise, a brain scan showing changed connectivity does not prove improved wellbeing. Cell or animal findings about plasticity cannot by themselves demonstrate lasting benefit in people. Ask what was measured, in whom, at which exposure and with what comparison. No substance use is needed to participate in this course or community.
Check your understanding: Why is the same dose label not comparable across all seven substances?
The mechanisms, potency, composition, routes and available human evidence differ. A label does not establish equivalent effects or equivalent safety.
LESSON 02LSD
Classic psychedelic · Human studies
LSD, or lysergic acid diethylamide, is a synthetic classic psychedelic. It is not a plant preparation. Its amount is often discussed in micrograms rather than milligrams, illustrating why a number without a unit is meaningless. Potency by weight does not tell you how manageable an experience will be.
How it works in the brain
LSD activates serotonin receptors, with 5-HT2A central to its psychedelic effects. Serotonin is a signaling molecule, not simply a “happiness chemical.” Changing receptor activity can alter perception, emotional processing and how experiences are interpreted. That does not mean the brain has been “reset.” NIH: LSD-related receptor research
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
Intended to stay below a full psychedelic experience. Controlled research has found some changes in arousal and attention, with substantial variation between people. A person may notice little, or may feel stimulation or a change in mood. These findings do not establish reliable improvements in conversation, creativity or social anxiety.
Low dose
Noticeable changes can emerge in sensory salience, thought flow and emotion. “Low” does not guarantee normal judgment or a comfortable response. Low-dose research does not show that everyone responds in the same direction.
Macro / full psychedelic dose
Stronger perceptual changes, altered time and sense of self, and difficult-to-express experiences can occur. A controlled comparison found that a higher LSD dose increased anxiety and impaired control without proportionally increasing every positive effect. LSD also lasted longer than psilocybin in that study.
What this means in a social setting
Some laboratory studies at fully psychedelic doses found increased feelings of closeness and emotional empathy, alongside reduced accuracy in recognizing some negative facial expressions. Feeling connected and accurately reading another person are not the same thing. Those studies were not tests of microdosing at parties. Controlled study of LSD and social processing
Risks and limits
For a social setting, the practical concern is prolonged altered judgment and possible overwhelm, not just whether visual effects occur. Do not use a subjective feeling of clarity as evidence that driving, supervision of others or important decisions are safe. More intense experiences are not a required next step.
Read the findings and their limits: Low-dose LSD and individual variability · Controlled LSD–psilocybin comparison. Brain measurements are not proof of lasting social benefit.
Check your understanding: Does feeling more trusting mean you are reading another person more accurately?
No. A feeling of closeness and accurate perception of social cues are different outcomes. Consent and boundaries still require explicit communication.
LESSON 03MDMA
Entactogen · Human studies
MDMA is a synthetic drug commonly described as an entactogen: a substance associated with emotional openness and connection. It has stimulant effects and is pharmacologically different from classic psychedelics. A product sold as “Molly” or “ecstasy” is not proof of its contents.
How it works in the brain
MDMA increases signaling by serotonin, norepinephrine and dopamine, mainly through effects on the transporters that normally help recycle these chemical messengers. It promotes release and alters reuptake. These systems influence mood and arousal as well as body functions; the mechanism is not simply “adding empathy.” NIDA: MDMA and neurotransmitters
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
There is no established, evidence-based MDMA microdosing protocol for social confidence or routine wellbeing in the sources reviewed here. A small amount should not be advertised as a predictable mini-version of a studied therapeutic session.
Low / lower active dose
Stimulation, emotional warmth or noticeable drug effects may occur, but the sought-after social effects are not guaranteed. Controlled research found dose-dependent cardiovascular and subjective effects. “Less noticeable” is not equivalent to no physiological effect.
Full active / higher dose
More pronounced euphoria, closeness and stimulation can occur, alongside increased heart rate and blood pressure. “Macrodose” is not a useful safety category for MDMA; taking more can increase toxicity rather than produce a better therapeutic or social experience.
What this means in a social setting
In a placebo-controlled study, MDMA increased desire for company at the higher studied dose while impairing recognition of angry and fearful faces. Emotional openness is not the same as informed consent, compatibility or sound judgment. MDMA social and emotional processing study
Risks and limits
Overheating, dehydration and dangerous low blood sodium are important risks. Drinking excessive water is not a solution to overheating and can worsen sodium imbalance. Hot, crowded environments add concerns. A regulated therapy study includes screening and support that an event does not provide. NHS: MDMA risks and emergency signs
Research on MDMA-assisted therapy is not evidence for casual social microdosing or frequent use. Example: controlled MDMA-assisted therapy trial. Do not change prescribed medication or combine substances to try to reproduce a study.
Check your understanding: Why not label MDMA a daily social microdose?
The evidence reviewed does not establish that use as safe or effective. Its transmitter-releasing and cardiovascular effects also differ from those of classic psychedelics.
LESSON 045-MAPB
Synthetic benzofuran · Mainly preclinical evidence
5-MAPB is a synthetic benzofuran associated with MDMA-like effects. It is not MDMA, not a botanical medicine and not an established substitute for a studied treatment. Similar names, chemical relationships or online comparisons do not create equivalent safety profiles.
How it works in the brain
Laboratory experiments using rat-brain preparations found that 5-MAPB acts at serotonin, norepinephrine and dopamine transporters to release those messengers. This helps explain an MDMA-like pharmacological profile. It does not establish what a particular human dose will do or whether repeated exposure is safe. The animal experiments in the same paper also studied related compounds; their results should not all be attributed directly to 5-MAPB. Primary benzofuran transporter study
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
No validated human social-microdosing range or reliable benefit profile was identified in the research reviewed. Describing a quantity as tiny does not resolve questions about identity, potency or long-term effects.
Low / lower active dose
MDMA-like warmth or stimulation is often used to describe this drug, but controlled human evidence is too limited to promise those effects or place them on a dependable dose ladder. This is an evidence gap, not evidence that the drug is mild.
Full active / higher dose
The likelihood and severity of adverse effects cannot be mapped reliably from online dose labels. A published human intoxication report describes serious cardiovascular, neurological and mental-status abnormalities. More should not be framed as a deeper version of connection.
What this means in a social setting
The appropriate course takeaway is uncertainty. A transporter mechanism may make an MDMA-like effect biologically plausible, but it does not demonstrate improved relationships, treatment of anxiety or suitability for a social event. Do not replace missing human evidence with a confident recommendation.
Risks and limits
A reported intoxication involved findings including elevated heart rate and blood pressure, agitation, disorientation and convulsions. A single case cannot tell us the frequency of those outcomes, but it rules out treating the absence of large trials as reassurance. Human 5-MAPB toxicity case report
The sources here are basic pharmacology and a clinical case report, not a social-microdosing trial. There is no supported conversion from an MDMA dose to a 5-MAPB dose in this course.
Check your understanding: Can a similar transporter profile justify using an MDMA dosing chart for 5-MAPB?
No. Mechanistic similarity is not dose equivalence. Human exposure, metabolism, potency, product identity and toxicity still require their own evidence.
LESSON 05Metocin · 4-HO-MET
Synthetic tryptamine · Limited human evidence
Metocin is another name for 4-HO-MET, a synthetic tryptamine related to psilocin. It is not psilocybin and should not be treated as interchangeable with mushrooms. A related chemical structure can support a research hypothesis without establishing the same experience, potency or safety.
How it works in the brain
Laboratory receptor studies show activity at serotonin receptors, including 5-HT2A, which is central to classic psychedelic effects. A receptor assay can show binding or activation in a controlled system. It cannot tell us that a person will remain sociable, avoid anxiety or benefit from repeated use. Primary tryptamine receptor study · Substituted-tryptamine pharmacology
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
A controlled human microdosing benefit or validated category was not identified in the research reviewed. Claims of effortless creativity or social ease should therefore be labeled unproven, not taught as expected outcomes.
Low / lower active dose
Reports describe perceptual, emotional and bodily changes, but a qualitative report cannot establish a predictable “low-dose” profile. The common idea of visuals without meaningful mental effects should not be treated as a guarantee.
Macro / full psychedelic dose
Published user-report analysis describes marked changes in thinking, perception, bodily experience and the sense of boundaries between self and surroundings. Experiences ranged from pleasurable to frightening. Those reports do not provide a controlled dose-response curve.
What this means in a social setting
A study analyzed 25 anonymous online accounts, not medically supervised dosing sessions. It is useful for understanding what people described, but weak evidence for predicting what will happen to someone at a gathering. The lesson is not “metocin is the social psychedelic.” It is that emotional and cognitive changes can accompany visual effects. Qualitative study of 4-HO-MET experiences
Risks and limits
Limited human research leaves important questions about repeated exposure, interactions and adverse-event rates unanswered. Avoid interpreting an informal reputation as proof that boundaries, judgment or mental state will remain unaffected.
Human reports and laboratory receptor results answer different questions. Neither establishes a safe personal amount, an approved treatment or a reliable social-microdosing routine.
Check your understanding: Why is “mostly visual, hardly any headspace” not an adequate safety description?
It reduces a variable psychedelic experience to a slogan. The available reports include changes in cognition and emotion as well as perception.
LESSON 06Psilocybin
Classic psychedelic · Human studies
Psilocybin occurs in certain mushrooms and is converted by the body into psilocin. Mushroom material and purified psilocybin are different preparations. A mass of dried mushrooms is not the same measurement as a mass of the active compound.
How it works in the brain
Psilocin acts at serotonin receptors, particularly 5-HT2A. This influences processes involved in perception and experience. It does not mean that every new thought is a more accurate thought or that a feeling of insight is evidence of a lasting brain repair. Serotonin-receptor pharmacology · NCCIH: psilocybin overview
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
A double-blind mushroom study found noticeable subjective effects but did not support broad improvements in wellbeing, creativity or cognition. An observational study reported improvements in mood, but without randomization it could not establish that the drug caused them. The evidence is mixed and design matters.
Low dose
Subtle-to-noticeable changes in emotion, sensory experience and thinking may occur. Nausea or anxiety can also occur. There is no universal point at which a mushroom preparation changes from imperceptible to perceptible for every person.
Macro / full psychedelic dose
Perceptual changes, altered time or self-experience and intense emotions become more prominent. Bliss or meaningful experiences are possible, but so are fear, confusion and impaired control. A clinical study found substantial overlap with LSD effects, while psilocybin was shorter acting.
What this means in a social setting
A claim that mushrooms improve sociability needs a study that actually measures social functioning. Mood improvement, a striking personal story and better communication are not interchangeable outcomes. An experience can feel connecting while making conversation or interpreting another person more difficult.
Risks and limits
NCCIH notes adverse effects including anxiety, nausea and increases in heart rate or blood pressure. Product variability makes mushroom weight an unreliable stand-in for a standardized active dose. Screening and support in clinical research matter; clinical findings should not be presented as a guarantee at a social gathering.
Compare designs: Double-blind psilocybin microdosing study · Observational microdosing study · Controlled comparison with LSD.
Check your understanding: Why can two studies reach different-looking conclusions about microdosing?
They may use different preparations, populations, outcomes and controls. Expectation and self-selection can affect observational results; small controlled trials also have limits.
LESSON 07DMT · N,N-DMT
Classic psychedelic · Route-specific human studies
Here, DMT means N,N-dimethyltryptamine. It is chemically different from 5-MeO-DMT. The name alone also does not identify the preparation or route. Research with intravenous DMT, inhaled DMT and ayahuasca should not be treated as one interchangeable experience.
How it works in the brain
DMT acts at serotonin receptors, especially 5-HT2A. A human EEG-fMRI study found changes in brain-network organization, including less separation between networks and increased connectivity in some regions. This is a description of measured brain activity, not proof of enhanced intelligence, access to external realities or a “brain reset.” Human DMT brain-imaging study
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
No established social-microdosing benefit or general-purpose protocol is supported by the sources reviewed here. A small exposure should not be presumed to improve conversation or preserve ordinary judgment.
Low / lower active dose
The amount, speed of delivery and route affect how quickly changes appear. A controlled intravenous study found dose-related subjective effects. Its findings are not a conversion chart for an inhaled or oral product.
Macro / full psychedelic dose
DMT can produce a rapid, immersive alteration in perception and sense of reality. Intense imagery, emotional shifts and difficulty staying oriented to the room can make ordinary interaction impractical. Higher doses in a controlled study produced more fear and negative effects than lower doses.
What this means in a social setting
Short duration does not mean mild intensity or suitability for a busy social setting. The course does not frame a rapid, immersive experience as a tool for mingling. A temporary inability to follow conversation or orient to surroundings matters even if the peak is brief.
Risks and limits
Ayahuasca is a different exposure involving additional alkaloids, including monoamine oxidase inhibitors. These alter drug handling and introduce important interaction concerns. Do not infer that results from one DMT formulation establish the safety of another, and do not confuse N,N-DMT with 5-MeO-DMT. DMT and ayahuasca safety evidence review
Controlled, route-specific DMT dose-response research. Medical supervision, known formulation and selected participants limit what can be inferred about unsupervised use.
Check your understanding: Does a short peak make DMT a low-impact social microdosing option?
No. Duration and intensity are separate. Rapid onset and loss of orientation can disrupt communication and safety even during a brief experience.
LESSON 08Bufo · 5-MeO-DMT
Different from N,N-DMT · Emerging clinical evidence
“Bufo” usually refers to secretion from the Colorado River toad, historically named Bufo alvarius, containing 5-MeO-DMT and other constituents. It is not a standardized dose of pure 5-MeO-DMT. Neither the secretion nor isolated 5-MeO-DMT is interchangeable with N,N-DMT.
How it works in the brain
5-MeO-DMT acts at serotonin receptors including 5-HT1A and 5-HT2A. Its substantial 5-HT1A activity helps distinguish its pharmacology from a simple “stronger DMT” description. Receptor and animal studies help explain possible mechanisms; they do not prove a human therapeutic effect or reveal the meaning of an experience. Primary study of 5-MeO-DMT receptor pharmacology
Effects across intensity levels
Descriptions, not dose instructions. Responses vary and the evidence differs by substance.
Microdose
A 2025 placebo-controlled Phase I study examined a specific sublingual 5-MeO-DMT formulation at sub-psychedelic doses. It reported tolerability and physiological findings in a selected sample. This does not establish the safety or benefit of social microdosing, inhaled exposure or toad secretion.
Low / lower active dose
A lower nominal amount does not ensure a gentle or reliably social experience. Early research found considerable variability between people. Route and formulation matter, so categories cannot be transferred from one preparation to another.
Macro / full psychedelic dose
Profound changes in self-experience and awareness can occur, sometimes described as loss of self-boundaries or a sense of unity. Overwhelming fear or distress is also possible. A person may not be able to communicate or remain oriented in an ordinary social environment.
What this means in a social setting
The early sublingual study is relevant emerging research, not a reason to market bufo as an event microdose. A Phase I tolerability result is not evidence of effectiveness for social anxiety, connection or any other claimed benefit. 2025 sublingual microdose study
Risks and limits
Combining 5-MeO-DMT with MAO inhibitors is particularly dangerous. A fatal mixed intoxication involving 5-MeO-DMT and harmala alkaloids has been reported. That case does not quantify every person’s risk, but it underscores why this is not an interchangeable ayahuasca ingredient or casual combination. Published fatal intoxication case
Early supervised 5-MeO-DMT dose-ranging study. Controlled formulations, medical screening and supervision are essential context. Toad-derived and synthetic products also raise different sourcing and quality questions; “natural” does not settle them.
Check your understanding: Can a sublingual 5-MeO-DMT study supply a dosing guide for bufo secretion?
No. The formulation, route, composition and study conditions differ. The study does not validate social use or a dose conversion.
Put the evidence in context
FOUR FOUNDATIONS
LESSON 09Language Before Labels
A shared vocabulary creates better questions
“Plant medicine” is a broad cultural phrase, not a single scientific category. Before evaluating any claim, identify the specific substance, practice and context being discussed. A ceremony, a clinical study and a social gathering can use similar language while operating very differently.
Psilocybin comes from certain mushrooms. Mushrooms are fungi, so not every substance included in the plant-medicine conversation is literally a plant. “Natural” describes an origin; it does not establish safety, quality or effectiveness.
Keep four questions separate: What is it? What does someone claim it does? What evidence supports that claim? What does the claim mean for this particular situation? A confident answer to the first question does not answer the other three.
- Psychedelic: a category of substances associated with changes in perception and experience, not a promise of insight.
- Microdosing: a term used for taking small amounts, not a standardized guarantee of an imperceptible or risk-free experience.
- Integration: reflection and follow-through, not proof that an interpretation is true.
Check your understanding: A product is described as natural. What can you conclude?
Only that a claim about its origin has been made. You still need specific evidence about identity, quality, risks and effects.
LESSON 10Culture, Context and Respect
Learn without flattening different traditions
Plant-medicine conversations often borrow words, images and practices from distinct communities. Treat those communities as living groups of people, not a single timeless tradition. Ask who is speaking, which tradition they mean and whether they have permission to share a particular practice.
Respect is practical. Credit the source of an idea. Do not record or share a ceremony, story or image without permission. Avoid presenting attendance at one workshop as authority to teach a tradition. When a source is missing, say so rather than filling the gap with an appealing origin story.
Also separate cultural meaning from a medical claim. A practice can carry personal or community significance without that significance demonstrating clinical effectiveness. Conversely, a research paper cannot explain the full cultural meaning of a practice.
Your reflection: Where might my curiosity turn into entitlement? What can I learn through listening, without demanding access to someone else’s practice?
Check your understanding: Does a powerful cultural story establish that a treatment works?
No. Cultural significance and evidence of a treatment effect are different questions. Neither should be used to erase the other.
LESSON 11Evidence Without the Hype
Match the conclusion to the evidence
Start by naming the exact claim. “People felt better” is incomplete without knowing who, compared with what, measured how and for how long. A testimonial tells you what one person reports. It cannot isolate which part of an experience caused the outcome.
Clinical research may include screening, supervision and psychological support. Results from that setting do not automatically apply to unsupervised or social use. The safety and effectiveness of microdosing remain unclear.
Use a five-question reading routine: Is there an original study? Who participated? Was there a comparison group? What outcome was actually measured? Which limitations did the researchers report? Also look for financial interests and whether a headline is stronger than the study’s conclusion.
Scenario: An advertisement combines a personal success story with a link to an unrelated study. Evaluate the story and the study separately. The presence of a scientific link does not validate every sentence around it.
Check your understanding: What should you do when the headline promises more than the study measured?
Use the narrower finding, name the limitations and avoid repeating the stronger promise. If you cannot access enough detail, leave the claim unverified.
LESSON 12Your Informed-Decision Toolkit
Make room for questions, pauses and a no
A useful decision process does not push toward participation. It creates room to learn, seek qualified guidance, postpone or decline. Separate interest in a community from a decision about a substance. You can belong, learn and attend a conversation without taking anything.
Psychedelics can involve physical and psychological risks. Personal health history and medication questions belong with a qualified healthcare professional. Do not stop or change prescribed treatment based on course material, a host’s reassurance or another participant’s story.
- What is being offered, and what is not included?
- What qualifications and scope of practice does the provider have?
- How are consent, privacy, emergencies and follow-up handled?
- Can I decline without pressure or financial surprises?
- Which personal questions should I bring to my clinician?
Completion self-check: Explain one term clearly, rewrite one exaggerated claim, identify one cultural-respect practice and name one boundary. This is a personal learning review, not a clinical qualification.
Check your understanding: If you remain uncertain after asking questions, have you failed the course?
No. Recognizing uncertainty and choosing to wait are valid informed decisions. Learning does not obligate participation.
Across every profile
SAFETY IS NOT A DOSE LABEL.
No comparison on this page establishes that a substance is appropriate for you. Discuss personal health, mental-health history and medications with a qualified clinician. Do not discontinue prescriptions to participate. This guide is not an exhaustive interaction checker.
Consent and judgment
Keep participation optional. Do not pressure someone to use a substance, share private information or accept touch. Avoid driving, swimming or responsibility for someone else’s safety while impaired. Feeling trusting is not a substitute for explicit consent.
Mixing and uncertainty
Do not treat one product’s name as proof of identity or purity. Combining substances or changing the route can change the risks. MDMA and 5-MAPB are not interchangeable; N,N-DMT and 5-MeO-DMT are different substances. MAO-inhibitor combinations warrant particular caution.
Recognize an emergency
Call emergency services for seizures, collapse, chest pain, serious breathing difficulty, severe overheating or inability to wake someone. Do not assume a medical emergency is a spiritual process. Stay with the person and tell responders what may have been taken.
Health-risk reference: NHS MDMA guidance. In the United States call 911 for a medical emergency. Nonurgent individual risk assessment needs a qualified healthcare professional.
Keep perspective
EDUCATION WITH CARE
This is general education, not medical advice, diagnosis, treatment or professional certification. No substance use is required. Personal health and medication questions belong with a qualified healthcare professional. Respect applicable laws, privacy and the right to decline.
Further reading: NCCIH: Psilocybin, evidence and risks · NCCIH: Know the Science. These sources inform the evidence discussion; the exercises are original learning activities.